BioAtla and GATC Health announced a $40 million special purpose vehicle (SPV) transaction to advance ozuriftamab vedotin (Oz‑V; CAB‑ROR2‑ADC) into a Phase 3 registrational study for second‑line-plus oropharyngeal squamous cell carcinoma (OPSCC). The financing structure is targeted to de‑risk late‑stage development for a CAB antibody‑drug conjugate and aligns an AI‑driven drug‑development partner with the clinical-stage biotech to accelerate pivotal testing.